Lasofoxifene (Pfizer).
Pfizer is developing lasofoxifene, an oral naphthalene derivative selective estrogen receptor modulator identified under a collaboration with Ligand, for the treatment of osteoporosis and vaginal atrophy. In August 2004, Pfizer submitted a New Drug Application to the Food and Drug Administration (FDA) seeking approval of lasofoxifene for the treatment of osteoporosis; however, in September 2005, the FDA issued a non-approvable letter.
Gennari
Luigi
L
University of Siena, Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, Policlinico Le Scotte, Siena, Italy. gennari@unisi.it
D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004345:Drug Industry; D020847:Estrogen Receptor Modulators / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism; D011759:Pyrrolidines / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D020847:Estrogen Receptor Modulators; D011759:Pyrrolidines; D013764:Tetrahydronaphthalenes; C111332:Lasofoxifene